CTSO Quote, Financials, Valuation and Earnings

Delcath Systems, Inc. has a net margin of -33.42% compared to CytoSorbents Corp.'s net margin of 4.04%. CytoSorbents Corp.'s return on equity of -89.32% beat Delcath Systems, Inc.'s return on equity of 1.59%.

CytoSorbents Corp. has a consensus price target of $5.25, signalling upside risk potential of 622.15%. On the other hand Delcath Systems, Inc. has an analysts' consensus of $22.33 which suggests that it could grow by 148.15%. Given that CytoSorbents Corp. has higher upside potential than Delcath Systems, Inc., analysts believe CytoSorbents Corp. is more attractive than Delcath Systems, Inc..

CytoSorbents Corp. has a beta of 1.393, which suggesting that the stock is 39.333% more volatile than S&P 500. In comparison Delcath Systems, Inc. has a beta of 0.373, suggesting its less volatile than the S&P 500 by 62.663%.

CytoSorbents Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Delcath Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytoSorbents Corp. pays -- of its earnings as a dividend. Delcath Systems, Inc. pays out -- of its earnings as a dividend.

CytoSorbents Corp. quarterly revenues are $9.5M, which are smaller than Delcath Systems, Inc. quarterly revenues of $20.6M. CytoSorbents Corp.'s net income of -$3.2M is lower than Delcath Systems, Inc.'s net income of $830K. Notably, CytoSorbents Corp.'s price-to-earnings ratio is -- while Delcath Systems, Inc.'s PE ratio is 1,034.48x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytoSorbents Corp. is 1.30x versus 4.29x for Delcath Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Quest Diagnostics, Inc. has a net margin of -33.42% compared to CytoSorbents Corp.'s net margin of 9.12%. CytoSorbents Corp.'s return on equity of -89.32% beat Quest Diagnostics, Inc.'s return on equity of 14.49%.

CytoSorbents Corp. has a consensus price target of $5.25, signalling upside risk potential of 622.15%. On the other hand Quest Diagnostics, Inc. has an analysts' consensus of $217.38 which suggests that it could grow by 2.97%. Given that CytoSorbents Corp. has higher upside potential than Quest Diagnostics, Inc., analysts believe CytoSorbents Corp. is more attractive than Quest Diagnostics, Inc..

CytoSorbents Corp. has a beta of 1.393, which suggesting that the stock is 39.333% more volatile than S&P 500. In comparison Quest Diagnostics, Inc. has a beta of 0.662, suggesting its less volatile than the S&P 500 by 33.785%.

CytoSorbents Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Quest Diagnostics, Inc. offers a yield of 1.52% to investors and pays a quarterly dividend of $0.80 per share. CytoSorbents Corp. pays -- of its earnings as a dividend. Quest Diagnostics, Inc. pays out 36.57% of its earnings as a dividend. Quest Diagnostics, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CytoSorbents Corp. quarterly revenues are $9.5M, which are smaller than Quest Diagnostics, Inc. quarterly revenues of $2.8B. CytoSorbents Corp.'s net income of -$3.2M is lower than Quest Diagnostics, Inc.'s net income of $256M. Notably, CytoSorbents Corp.'s price-to-earnings ratio is -- while Quest Diagnostics, Inc.'s PE ratio is 24.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytoSorbents Corp. is 1.30x versus 2.16x for Quest Diagnostics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Danaher Corp. has a net margin of -33.42% compared to CytoSorbents Corp.'s net margin of 17.3%. CytoSorbents Corp.'s return on equity of -89.32% beat Danaher Corp.'s return on equity of 7.02%.

CytoSorbents Corp. has a consensus price target of $5.25, signalling upside risk potential of 622.15%. On the other hand Danaher Corp. has an analysts' consensus of $264.91 which suggests that it could grow by 26.53%. Given that CytoSorbents Corp. has higher upside potential than Danaher Corp., analysts believe CytoSorbents Corp. is more attractive than Danaher Corp..

CytoSorbents Corp. has a beta of 1.393, which suggesting that the stock is 39.333% more volatile than S&P 500. In comparison Danaher Corp. has a beta of 0.916, suggesting its less volatile than the S&P 500 by 8.434%.

CytoSorbents Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Danaher Corp. offers a yield of 0.61% to investors and pays a quarterly dividend of $0.32 per share. CytoSorbents Corp. pays -- of its earnings as a dividend. Danaher Corp. pays out 25.36% of its earnings as a dividend. Danaher Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CytoSorbents Corp. quarterly revenues are $9.5M, which are smaller than Danaher Corp. quarterly revenues of $6.8B. CytoSorbents Corp.'s net income of -$3.2M is lower than Danaher Corp.'s net income of $1.2B. Notably, CytoSorbents Corp.'s price-to-earnings ratio is -- while Danaher Corp.'s PE ratio is 41.45x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytoSorbents Corp. is 1.30x versus 6.10x for Danaher Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Odyssey Health, Inc. has a net margin of -33.42% compared to CytoSorbents Corp.'s net margin of --. CytoSorbents Corp.'s return on equity of -89.32% beat Odyssey Health, Inc.'s return on equity of --.

CytoSorbents Corp. has a consensus price target of $5.25, signalling upside risk potential of 622.15%. On the other hand Odyssey Health, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that CytoSorbents Corp. has higher upside potential than Odyssey Health, Inc., analysts believe CytoSorbents Corp. is more attractive than Odyssey Health, Inc..

CytoSorbents Corp. has a beta of 1.393, which suggesting that the stock is 39.333% more volatile than S&P 500. In comparison Odyssey Health, Inc. has a beta of -1.030, suggesting its less volatile than the S&P 500 by 202.982%.

CytoSorbents Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Odyssey Health, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CytoSorbents Corp. pays -- of its earnings as a dividend. Odyssey Health, Inc. pays out -- of its earnings as a dividend.

CytoSorbents Corp. quarterly revenues are $9.5M, which are larger than Odyssey Health, Inc. quarterly revenues of --. CytoSorbents Corp.'s net income of -$3.2M is lower than Odyssey Health, Inc.'s net income of -$483.4K. Notably, CytoSorbents Corp.'s price-to-earnings ratio is -- while Odyssey Health, Inc.'s PE ratio is 0.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CytoSorbents Corp. is 1.30x versus -- for Odyssey Health, Inc.. Usually stocks with elevated PS ratios are considered overvalued.